Search
Invitrogen
Mouse IL-27 Recombinant Protein
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
14-8271-63
Product Specifications
Expression System
HEK293 cells
Class
Recombinant
Type
Protein
Conjugate
Form
Liquid
Concentration
0.1 mg/mL
Amount
10 µg
Storage conditions
-80°C
Shipping conditions
Dry ice
Product Specific Information
Description: IL-27, a member of the IL-12 family, is a heterodimeric protein consisting of the p40-related protein Epstein-Barr virus-induced gene 3 (EBI3) non-covalently linked to an IL-12p35-related protein, p28 (also known as IL-30). IL-27 is produced by activated APCs and mature dendritic cells. IL-27 exerts its activities on NK cells and naive CD4+ T cells; mRNA expression analysis of IL-27 receptor components (WSX-1/TCCR and gp130) suggests that IL-27 may also target other cells, including mast cells and monocytes. Binding of IL-27 to WSX-1/gp130 activates JAK1, STAT1, and STAT3 and STAT1/3 phosphorylation. WSX-1/TCCR-deficient mice develop impaired Th1 responses and are more susceptible to infection with L. monocytogenes suggesting that Th1 responses require IL-27. Although activation of WSX-1 is required for the initiation of Th1 responses, it is not necessary for maintaining Th1 responses. IL-27 alone is not able to induce the differentiation of CD4+ T cells into IFN-gamma-producing cells, suggesting a role for IL-27 as an initial activator of Th1 responses. An important effect of IL-27 in initiating Th1 responses is the induction of the Th1-specific transcription factor T-bet as well as the suppression of the Th2-specific transcription factor GATA-3. T-bet plays a critical role in Th1 differentiation by its ability to maintain IL-12Rbeta2 expression following CD4+ T cell activation.
Recent studies indicate that IL-27 has a potent antitumor activity. In vitro, IL-27 has been found to act directly on naive CD8 cells, generating CTL with enhanced granzyme B expression. In vivo, IL-27 has been reported to augment CTL activity, inhibit tumor growth, and induce complete regression of primary and metastatic neuroblastoma tumors.
Applications Reported: The recombinant mouse IL-27 (EBI3/p28) has been reported useful for bioassay.
Applications Tested: This recombinant mouse IL-27 (EBI3/p28) has been tested in bioassay for inhibition of IL-2 production by mouse splenocytes activated with immobilized anti-CD3 and soluble anti-CD28 antibodies (Villarino, A.V., et al. 2006. J. Immunol. 176: 237). The ED50 for this is typically 50 ng/mL, corresponding to a specific activity of 2.0 x 10e4 Units/mg.
Source: Mouse EBI3 met 1-pro 228; accession # BC008209 linked through a gly-gly-gly-gly-Ser3 to mature P28/IL-30 phe 29-Ser 234; accession # NM_145636 tagged at the C-terminal with thr-gly-his10 was expressed in human 293 cells.
Bioactivity: Measured in a bioassay of IL-27-mediated inhibition of IL-2 production by mouse splenocytes activated with immobilized anti-CD3 and soluble anti-CD28 antibodies (Villarino, A.V., et al. 2006. J. Immunol. 176: 237). The ED50 for this is typically 50 ng/mL, corresponding to a specific activity of 2.0 x 10e4 Units/mg.
Endotoxin: Less than 0.01 ng/ug cytokine as determined by the LAL assay. Purity: >98% as determined by SDS-PAGE.
Molecular Weight: After removal of the secretion signal the mature EBI3-linker-mature P28-His10 protein has a predicted molecular mass of approximately 49,000. On non-reducing and reducing SDS-PAGE the linked protein migrates as a 55 kDa protein due to glycosylation.
Storage and handling: For best recovery, quick-spin vial prior to opening. Use in a sterile environment.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Target Information
IL-27 (Interleukin 27) is a cytokine belonging to the IL-12 family, and is a heterodimeric cytokine composed of EBI3 and p28 subunits. IL-27 is produced by activated dendritic cells and macrophages in response to Toll-like receptor ligands and pro-inflammatory cytokines. IL-27 promotes CD4+ T cell differentiation to the Th1 lineage by inducing expression of the transcription factor T-bet and up regulating IL-12R beta2, which in turn suppresses Th2 and Th17 differentiation and proliferation. IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. IL-27 acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting IL-27 involvement in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. In humans, the gene is located on the p arm of chromosome 16.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support